Washington, D.C. - The National Infusion Center Association applauds a letter sent by Members of the Tennessee congressional delegation to BlueCross BlueShield of Tennessee raising concerns that its planned changes to payment for infused drugs may hamper patient access to care.

The May 27th letter signed by five members of the Tennessee delegation -- Reps. Phil Roe, Scott Dejaralais, Tim Burchett, Mark Green and Chuck Fleischmann – said, “We are concerned that replacing the current ‘buy-and-bill’ distribution system in the midst of the 2019 novel coronavirus (COVID-19) pandemic with a model that requires providers to order specialty medications exclusively from pharmacies may disrupt ongoing treatment for patients with chronic conditions and disparately impact the specialty provider community.”

Brian Nyquist, Executive Director of the National Infusion Center Association, said. “Our infusion providers who deliver care at a fraction of the cost of hospitals and in a more patient-friendly environment have been concerned about their ability to provide care with this drastic proposed change in reimbursement from Blue Cross BlueShield of Tennessee. We commend the Members of the Tennessee delegation for raising these concerns about patient access and hope TN BCBS can work with our providers and physician practices to ensure our patients continue to receive needed therapy without interruption.”

The National Infusion Center Association provides a national advocacy voice for non-hospital, non-oncology in-office infusion to improve access to safe, high-quality, cost effective care.